Literature DB >> 22438535

Computational reconstruction of Bole1a, a representative synthetic hepatitis C virus subtype 1a genome.

Supriya Munshaw1, Justin R Bailey, Lin Liu, William O Osburn, Kelly P Burke, Andrea L Cox, Stuart C Ray.   

Abstract

Hepatitis C virus (HCV) research is hampered by the use of arbitrary representative isolates in cell culture and immunology. The most replicative isolate in vitro is a subtype 2a virus (JFH-1); however, genotype 1 is more prevalent worldwide and represents about 70% of infections in the United States, and genotypes differ from one another by 31% to 33% at the nucleotide level. For phylogenetic and immunologic analyses, viruses H77 and HCV-1 (both subtype 1a) are commonly used based on their historic importance. In an effort to rationally design a representative subtype 1a virus (Bole1a), we used Bayesian phylogenetics, ancestral sequence reconstruction, and covariance analysis on a curated set of 390 full-length human HCV 1a sequences from GenBank. By design, Bole1a contains variations present in widely circulating strains and matches more epitope-sized peptides in a full-genome comparison to subtype 1a isolates than any other sequence studied. Parallel analyses confirm that selected epitopes from the Bole1a genome were able to elicit a robust T cell response. In a proof of concept for infectivity, the envelope genes (E1 and E2) of Bole1a were expressed in an HIV pseudoparticle system containing HCV envelope genes and HIV nonenvelope genes with luciferase expression. The resulting Bole1a pseudoparticle robustly infected Hep3B cells. In this study, we demonstrate that a rationally designed, fully synthetic HCV genome contains representative epitopes and envelope genes that assemble properly and mediate entry into target cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22438535      PMCID: PMC3347276          DOI: 10.1128/JVI.05959-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C.

Authors:  Andrea L Cox; Timothy Mosbruger; Georg M Lauer; Drew Pardoll; David L Thomas; Stuart C Ray
Journal:  Hepatology       Date:  2005-07       Impact factor: 17.425

2.  Founder effects in the assessment of HIV polymorphisms and HLA allele associations.

Authors:  Tanmoy Bhattacharya; Marcus Daniels; David Heckerman; Brian Foley; Nicole Frahm; Carl Kadie; Jonathan Carlson; Karina Yusim; Ben McMahon; Brian Gaschen; Simon Mallal; James I Mullins; David C Nickle; Joshua Herbeck; Christine Rousseau; Gerald H Learn; Toshiyuki Miura; Christian Brander; Bruce Walker; Bette Korber
Journal:  Science       Date:  2007-03-16       Impact factor: 47.728

3.  Detection of diverse hepatitis C virus (HCV)-specific cytotoxic T lymphocytes in peripheral blood of infected persons by screening for responses to all translated proteins of HCV.

Authors:  D K Wong; D D Dudley; P B Dohrenwend; G M Lauer; R T Chung; D L Thomas; B D Walker
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

4.  Production of infectious hepatitis C virus in tissue culture from a cloned viral genome.

Authors:  Takaji Wakita; Thomas Pietschmann; Takanobu Kato; Tomoko Date; Michiko Miyamoto; Zijiang Zhao; Krishna Murthy; Anja Habermann; Hans-Georg Kräusslich; Masashi Mizokami; Ralf Bartenschlager; T Jake Liang
Journal:  Nat Med       Date:  2005-06-12       Impact factor: 53.440

Review 5.  Cellular immune responses against hepatitis C virus: the evidence base 2002.

Authors:  S Ward; G Lauer; R Isba; B Walker; P Klenerman
Journal:  Clin Exp Immunol       Date:  2002-05       Impact factor: 4.330

6.  Robust hepatitis C virus infection in vitro.

Authors:  Jin Zhong; Pablo Gastaminza; Guofeng Cheng; Sharookh Kapadia; Takanobu Kato; Dennis R Burton; Stefan F Wieland; Susan L Uprichard; Takaji Wakita; Francis V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-06       Impact factor: 11.205

7.  Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles.

Authors:  Mayla Hsu; Jie Zhang; Mike Flint; Carine Logvinoff; Cecilia Cheng-Mayer; Charles M Rice; Jane A McKeating
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-21       Impact factor: 11.205

8.  The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes.

Authors:  A L Erickson; Y Kimura; S Igarashi; J Eichelberger; M Houghton; J Sidney; D McKinney; A Sette; A L Hughes; C M Walker
Journal:  Immunity       Date:  2001-12       Impact factor: 31.745

9.  Efficient initiation of HCV RNA replication in cell culture.

Authors:  K J Blight; A A Kolykhalov; C M Rice
Journal:  Science       Date:  2000-12-08       Impact factor: 47.728

10.  Cellular immune selection with hepatitis C virus persistence in humans.

Authors:  Andrea L Cox; Timothy Mosbruger; Qing Mao; Zhi Liu; Xiao-Hong Wang; Hung-Chih Yang; John Sidney; Alessandro Sette; Drew Pardoll; David L Thomas; Stuart C Ray
Journal:  J Exp Med       Date:  2005-06-06       Impact factor: 14.307

View more
  16 in total

1.  Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms.

Authors:  Madeleine C Mankowski; Valerie J Kinchen; Lisa N Wasilewski; Andrew I Flyak; Stuart C Ray; James E Crowe; Justin R Bailey
Journal:  Proc Natl Acad Sci U S A       Date:  2017-12-18       Impact factor: 11.205

2.  Constraints on viral evolution during chronic hepatitis C virus infection arising from a common-source exposure.

Authors:  Justin R Bailey; Sarah Laskey; Lisa N Wasilewski; Supriya Munshaw; Liam J Fanning; Elizabeth Kenny-Walsh; Stuart C Ray
Journal:  J Virol       Date:  2012-09-12       Impact factor: 5.103

3.  Immunogenicity and cross-reactivity of a representative ancestral sequence in hepatitis C virus infection.

Authors:  Kelly P Burke; Supriya Munshaw; William O Osburn; Jordana Levine; Lin Liu; John Sidney; Alessandro Sette; Stuart C Ray; Andrea L Cox
Journal:  J Immunol       Date:  2012-04-16       Impact factor: 5.422

4.  Plasma deconvolution identifies broadly neutralizing antibodies associated with hepatitis C virus clearance.

Authors:  Valerie J Kinchen; Guido Massaccesi; Andrew I Flyak; Madeleine C Mankowski; Michelle D Colbert; William O Osburn; Stuart C Ray; Andrea L Cox; James E Crowe; Justin R Bailey
Journal:  J Clin Invest       Date:  2019-08-13       Impact factor: 14.808

5.  Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance.

Authors:  Justin R Bailey; Lisa N Wasilewski; Anna E Snider; Ramy El-Diwany; William O Osburn; Zhenyong Keck; Steven K H Foung; Stuart C Ray
Journal:  J Clin Invest       Date:  2014-12-15       Impact factor: 14.808

6.  Impact of sequence variation in a dominant HLA-A*02-restricted epitope in hepatitis C virus on priming and cross-reactivity of CD8+ T cells.

Authors:  Susanne Ziegler; Kathrin Skibbe; Andreas Walker; Xiaoyu Ke; Falko M Heinemann; Andreas Heinold; Juk Yee Mok; Wim J E van Esch; Dongliang Yang; Matthias Wölfl; Jörg Timm
Journal:  J Virol       Date:  2014-07-09       Impact factor: 5.103

7.  CD4+ T-cell recovery with suppressive ART-induced rapid sequence evolution in hepatitis C virus envelope but not NS3.

Authors:  Lin Liu; David Nardo; Eric Li; Gary P Wang
Journal:  AIDS       Date:  2016-03-13       Impact factor: 4.177

8.  A Hepatitis C Virus Envelope Polymorphism Confers Resistance to Neutralization by Polyclonal Sera and Broadly Neutralizing Monoclonal Antibodies.

Authors:  Lisa N Wasilewski; Ramy El-Diwany; Supriya Munshaw; Anna E Snider; Jillian K Brady; William O Osburn; Stuart C Ray; Justin R Bailey
Journal:  J Virol       Date:  2016-01-27       Impact factor: 5.103

9.  Antiretroviral therapy for HIV and intrahepatic hepatitis C virus replication.

Authors:  Jeffrey R Quinn; Ashish Goyal; Ruy M Ribeiro; Guido Massaccesi; Justin R Bailey; David L Thomas; Ashwin Balagopal
Journal:  AIDS       Date:  2022-03-01       Impact factor: 4.632

Review 10.  Structure-Based and Rational Design of a Hepatitis C Virus Vaccine.

Authors:  Johnathan D Guest; Brian G Pierce
Journal:  Viruses       Date:  2021-05-05       Impact factor: 5.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.